Table 3.
Clinical and laboratory data of AAV patients in G1 and G2 subgroups.
| G1 (n = 90) | G2 (n = 51) | P-value | |
|---|---|---|---|
| Age, Median (IQR) | 60.3 (52.7, 66.7) | 58.6 (51.0, 70.2) | 0.597 |
| Male, n (%) | 37 (41.1) | 28 (54.9) | 0.114 |
| Smoke, n (%) | 23 (25.6) | 14 (27.5) | 0.806 |
| Hypertension, n (%) | 42 (46.7) | 25 (49.0) | 0.340 |
| Scr at admission, μmol/l, Median (IQR) | 257.0 (162.0, 384.5) | 209.0 (157.5, 287.0) | 0.075 |
| Baseline Scr, μmol/l, Median (IQR) | 117.0 (81.2, 155.5) | 134.0 (99.0, 190.0) | 0.070 |
| Urine red blood cell/ul, Median (IQR) | 406.1 (134.3, 1302.9) | 139.3 (77.9, 631.2) | 0.006 |
| White blood cell × 109/L, Median (IQR) | 7.6 (5.4, 10.0) | 8.5 (6.6, 10.4) | 0.063 |
| Hemoglobin g/L, Median (IQR) | 83.0 (76.2, 95.0) | 82.0 (71.5, 101.5) | 0.555 |
| Platelet×109/L, Median (IQR) | 217.0 (167.8, 291.8) | 244.0 (182.0, 303.5) | 0.298 |
| 24 h urine protein g/L, Median (IQR) | 1.7 (1.0, 2.7) | 1.9 (0.7, 3.3) | 0.324 |
| Albumin g/L, Median (IQR) | 32.6 (28.1, 36.7) | 31.0 (27.1, 35.0) | 0.284 |
| Globulin g/L, Median (IQR) | 30.5 (27.0, 33.2) | 29.5 (25.9, 35.0) | 0.804 |
| CRP mg/L, Median (IQR) | 21.5 (6.6, 58.4) | 33.1 (4.6, 101.7) | 0.109 |
| MPO-ANCA positive, n (%) | 67(74.4) | 37 (68.5) | 0.806 |
| MPO, Median (IQR) | 53.1 (20.3, 116.0) | 42.7 (17.9, 94.8) | 0.138 |
| PR3-ANCA positive, n (%) | 10 (11.1%) | 6 (11.8%) | 0.906 |
| PR3, Median (IQR) | 1.5 (1.1, 2.8) | 1.3 (1.1, 2.0) | 0.382 |
| BVAS, Mean ± std. | 16.6 ± 3.7 | 15.8 ± 4.2 | 0.175 |
| VDI at admission, Median (IQR) | 0 (0, 1) | 0 (0, 1) | 0.117 |
| AKI stage, n (%) | 0.154 | ||
| Stage 1 | 24 (26.7) | 19 (37.3) | |
| Stage 2 | 33 (36.7) | 11 (21.6) | |
| Stage 3 | 33 (36.7) | 21 (41.2) | |
| Treatments, n (%) | |||
| I.V. Pulse Methylprednisolone | 58 (64.4) | 26 (51.0) | 0.117 |
| Plasma exchange | 3 (3.3) | 2 (3.9) | 0.856 |
| Immunosuppressants, n (%) | |||
| CTX | 42 (46.7) | 26 (51.0) | 0.622 |
| MMF | 42 (40.0) | 16 (27.5) | 0.093 |
| Renal biopsy, n (%) | 64 (71.1) | 32 (62.7) | 0.496 |
| Status at 3-month, n (%) | |||
| Withdrew dialysis | 14 (15.6) | 5 (9.8) | <0.001 |
| Dialysis | 0 (0) | 18 (35.3) | |
| Death | 0 (0) | 2 (2.1) | |
| Long-term outcome | |||
| Death, n (%) | 8 (8.9) | 14 (27.5) | 0.007 |
| Survival time, month, Median (IQR) |
56.5 (27.5, 82.0) | 41.0 (24.5, 86.0) | 0.480 |
| Renal endpoint, n (%) | 12 (13.3) | 24 (47.1) | <0.001 |
| Renal survival time, month, Median (IQR) |
48.0 (26.2, 80.8) | 24.0 (3.0, 39.0) | <0.001 |
| Composite endpoint, n (%) | 16 (17.8) | 28 (55.0) | <0.001 |
Scr, serum creatinine; MPO, myeloperoxidase; BVAS, Birmingham Vasculitis Activity Score; CTX, cyclophosphamide; MMF, mycophenolate mofetil; VDI, vascular damage index.
Bolded value: P-value < 0.05.